RENOWN NEWSROOM

Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

Read More About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

Renown joins Washoe County Health District to Offer COVID-19 Vaccines to Children 5-11 at Vaccine Clinics. Renown Health is partnering with the Washoe County Health District to help distribute the initially available, limited supplies of an age-appropriate dose of the COVID-19 Pfizer-BioNTech vaccines to children ages 5-11. At this time, all residents 5 years and older are eligible to receive a vaccine. Renown announced today that for parents/guardians with proxy access for their children through the Renown MyChart app, vaccination appointments are now available for children ages 5-11. Pending supply, Renown expects to be able to vaccinate 1,600 children with the 2-dose series in a limited series of weekend clinics. At this time, due to limited supplies, no vaccines for children are available through Renown Medical Group pediatric offices. Vaccine appointments may only be scheduled through the Renown MyChart app; please do not contact a Renown doctor/health care provider or the Engagement Center at this time. There is no cost to establish a Renown MyChart account, and you do not need to have a Renown provider to enroll. For MyChart Technical Support, call 775-982-2781. Renown is covering all costs of the vaccine, and it is offered free of charge. “As a pediatrician, an intensive care physician, a public health practitioner and a grandparent, I encourage parents to vaccinate their children against COVID-19 now. No child should suffer, be hospitalized or die from a disease that can prevented by simply getting a shot,” says Tony Slonim, MD, DrPH, President & CEO of Renown Health. “We remain steadfast in fighting the good fight for our community, and that includes protecting kids. Being able to serve kids and their parents, with the only Children’s Hospital in northern Nevada, and being able to administer COVID-19 vaccines to children is incredibly gratifying for our team. This vaccine will prevent deaths, ICU admissions and will prevent significant long-term adverse outcomes in children." “I tell parents, get your kids vaccinated now- because every kid is at risk,” says Kristina Deeter, M.D., MBA, Pediatric Intensivist, and Vice Chair of Pediatrics at Renown Children’s Hospital. “Please get your family- including your kids, vaccinated now to keep your family safe. Being fully vaccinated and being able to hug Grandma and Grandpa at the holidays may be the greatest gift of all this holiday season.” “The CDC recommends everyone ages 5 and older get a COVID-19 vaccine to help protect against COVID-19. Widespread vaccination for COVID-19 is a critical tool to protect everyone, especially those at highest risk, from severe illness and death. Currently, the Pfizer vaccine is the only option currently authorized for children,” says Vanessa Slots, MD, a pediatrician with Renown Children’s. “It was found to give kids strong protection against COVID-19, including against the Delta variant. Children who are vaccinated may have some side effects (chills, redness and swelling at site injection), which are normal signs that their body is building protection.” Children are advised not to receive the vaccine if: • They are ill at the time of vaccination (fever, shortness of breath, vomiting, diarrhea or acute illness). • They have been diagnosed with COVID-19 in the previous 14 days. • They have a history of significant allergic reaction to any of the ingredients in the vaccine.   About Renown Health Renown Health is the region’s largest not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.

Read More About The Greatest Gift of All? A Fully Vaccinated Family!